P-selectin binds to the N-terminal region of human P-selectin glycoprotein ligand-1 (PSGL-1). For optimal binding, this region requires sulfation on three tyrosines and specific core-2 O-glycosylation on a threonine. P-selectin is also thought to bind to the N terminus of murine PSGL-1, although it has a very different amino acid sequence than human PSGL-1. Murine PSGL-1 has potential sites for sulfation at Tyr-13 and -15 and for O-glycosylation at Thr-14 and -17. We expressed murine PSGL-1 or constructs with substitutions of these residues in transfected Chinese hamster ovary cells that coexpressed the glycosyltransferases required for binding to P-selectin. The cells were assayed for binding to fluid-phase P-selectin and for tethering and rolling on P-selectin under flow. In both assays, substitution of Tyr-13 or Thr-17 markedly diminished, but did not eliminate, binding to P-selectin. In contrast, substitution of Tyr-15 or Thr-14 did not affect binding. Substitution of all four residues eliminated binding. Treatment of cells with chlorate, an inhibitor of sulfation, markedly reduced binding of wild-type PSGL-1 to P-selectin but did not further decrease binding of PSGL-1 with substitutions of both tyrosines. These data suggest that sulfation of Tyr-13 and O-glycosylation of Thr-17 are necessary for murine PSGL-1 to bind optimally to P-selectin. Because it uses only one tyrosine, murine PSGL-1 may rely more on other peptide components and Oglycosylation to bind to P-selectin than does human PSGL-1.
Introduction
Leukocyte recruitment into lymphoid tissues or sites of inflammation begins with circulating leukocytes tethering to and then rolling on the vessel wall. Interactions of selectin adhesion receptors with cell-surface glycoconjugates mediate th is first critical event, which precedes firm adhesion and then emigration of leukocytes into underlying tissues 1, 2 . L-selectin, expressed on leukocytes, binds to ligands on some endothelial cells and on other leukocytes. E-selectin, expressed on cytokine-activate d endothelial cells, binds to ligands on leukocytes. P-selectin, expressed on activated platelets and endothelial cells, binds to ligands on leukocytes, platelets, and some endothelial cells.
Adhesion requires binding of the C-type carbohydrate recognition domain at the N terminus of each selectin to glycans capped with 2-3-sialylated and 1-3-fucosylated structures such as sialyl Lewis x (sLe x ) 3 . However, selectins bind with higher affinity or avidity to a small subset of glycoproteins on blood or vascular cells 4 .
The best characterized glycoprotein ligand for selectins is P-selectin glycoprotein ligand-1 (PSGL-1), an extended homodimeric mucin on leukocytes that binds to all three selectins 2, 5 . Interactions with PSGL-1 are required for leukocytes to roll optimally on Pand L-selectin under flow. The structural requirements for binding of PSGL-1 to P-and L-selectin have been most extensively studied in human cells. Monoclonal antibodies (mAbs) that block leukocyte rolling on P-and L-selectin bind to short protein epitopes near the N terminus of mature PSGL-1 [6] [7] [8] [9] [10] [11] [12] . The binding site for P-and L-selectin, which encompasses the epitopes, includes three tyrosines in a consensus motif favoring tyrosine sulfation that are located 6 to 11 residues from a threonine residue [13] [14] [15] . Both tyrosine sulfation and specific O-glycosylation of the threonine are required for binding to P-
For personal use only. on . by guest www.bloodjournal.org From 4 selectin. Recombinant human PSGL-1 expressed in transfected Chinese hamster ovary (CHO) cells binds P-selectin if it is expressed with a core-2 1-6-Nacetylglucosaminyltransferase (e.g. Core2GlcNAcT-I) and an 1-3 fucosyltransferase (e.g. FTVII), first suggesting that PSGL-1 must be modified with a core-2 O-glycan(s) capped with sLe x 16 . Mutational analysis revealed that each tyrosine contributes to binding 17, 18 ; substitution of all three tyrosines with phenylalanines eliminates binding in biochemical and cell adhesion assays 14, 15, 17 . Similarly, substitution of the threonine with alanine eliminates binding. Glycosulfopeptides modeled after this region of human PSGL-1 have more specifically elucidated the structural requirements for binding to Pselectin 19, 20 . Sulfation of each tyrosine enhances binding affinity, and the O-glycan requires a core-2 branched structure capped with sLe x . The fucose makes a major contribution to binding affinity, whereas the sialic acid residue makes a lesser contribution. Remarkably, a tri -sulfated glycosulfopeptide with an isomeric extended core-1 O-glycan capped with sLe x does not bind to P-selectin. These data reveal specific stereochemical requirements for binding. This conclusion is supported by a co-crystal structure of human P-selectin complexed with the N-terminal region of human PSGL-1 21 . The C-type carbohydrate-recognition domain of P-selectin makes contacts with fucose, sialic acid, two of the three tyrosine sulfates, and certain other amino acids in the N-terminal region of PSGL-1. The structure suggests that these various components of PSGL-1 must be presented in an optimal configuration to bind productively to P-selectin.
Like human PSGL-1, murine PSGL-1 is a homodimeric sialomucin 22, 23 . mAbs to N-terminal peptide epitopes of PSGL-1 block rolling of murine leukocytes on murine Pselectin in vitro and in vivo [24] [25] [26] , and studies with PSGL-1-deficient mice confirm that PSGL-1 is the dominant ligand for P-selectin in murine leukocytes [27] [28] [29] . Studies with
For personal use only. on September 14, 2017. by guest www.bloodjournal.org From glycosidases, expression of PSGL-1 and glycosyltransferases in transfected cells, and analysis of leukocytes from mice deficient in FTVII, FTIV, or Core2GlcNAcT-I suggest that murine PSGL-1 requires modification with one or more core-2 O-glycans capped with sLe x 22,30-33 . Glycosulfopeptides modeled after the N-terminal region of human PSGL-1 inhibit rolling of murine leukocytes on P-selectin in vivo 34 . All these data suggest that murine PSGL-1 binds to P-selectin much like human PSGL-1. However, the N-terminal sequence of murine PSGL-1 shares little similarity with that of human PSGL-1 23, 35 . Murine PSGL-1 has only two tyrosines in a consensus sequence favoring tyrosine sulfation. There are also two nearby threonines that are candidates for attaching Oglycans required for binding. However, the spacing of these residues in the primary sequence is considerably closer than the corresponding residues in the human sequence.
Given the apparent stereochemical requirements for binding of human PSGL-1 to Pselectin, the different sequence in murine PSGL-1 makes it likely that it uses a different configuration of residues to bind to P-selectin. To address this issue, we expressed wildtype murine PSGL-1 and murine PSGL-1 constructs with substitutions in various Nterminal residues in transfected CHO cells that co-expressed Core2GlcNAcT-I and FTVII. Binding of PSGL-1 to P-selectin was measured by flow cytometry and by cell adhesion assays under flow.
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Materials and Methods
Materials Dulbecco's modified Eagle's medium (DMEM), G418 sulfate, hypoxanthine-thymidine, and nonessential amino acids were purchased from Gibco BRL.
Glutamine/penicillin/streptomycin were purchased from Irvine Scientific. Bovine serum and 25% human serum albumin were purchased from Summit Biotechnology and Aventis Behring, respectively. NuSerum was purchased from Collaborative Research. Transfections CHO DHFR(-) cells were maintained in DMEM containing 10% fetal calf serum, 1% hypoxanthine-thymidine, 0.1 mM nonessential amino acids, 1%
penicillin-streptomycin, and 2 mM glutamine. Transfected cells were also maintained in selection antibiotics as described 17, 18 . A clone of transfected CHO cells stably expressing
Core2GlcNAcT-I and FTVII was transfected with empty pZeoSV2 (+) or with pZeoSV2(+) containing wild-type or mutant murine PSGL-1 constructs, using anti-murine P-selectin mAb RB40.34 40 . In some experiments, human recombinant soluble P-selectin 41 was immobilized on the dish. Transfected CHO cells (10 6 /ml in HBSS/HSA) were perfused over the substrates at varying wall shear stresses 18, 42 . The accumulated number of rolling cells was measured after 4 min of perfusion by using a videomicroscopy system coupled to a digitized image analysis system (Inovision) on a Silicon Graphics workstation. For each experiment, adherent cells in 10-12 20x fields were counted. To measure resistance to detachment under flow, cells were allowed to accumulate at 0.5 dyn/cm 2 , and cell-free buffer was then introduced. Wall shear stress was increased every 30 s, and the percentage of remaining adherent cells was determined.
The rate that cells tethered to P-selectin was measured during the first 60 s of perfusion.
Cells that detached in less than 30 frames were defined as transient tethers. Cells that remained attached for at least 30 frames were defined as rolling tethers.
Results

Expression of wild-type or mutant murine PSGL-1 in CHO cells expressing
Core2GlcNAcT-I and FTVII--Both human and murine PSGL-1 are extended sialomucins that are expressed as homodimers. Each has a signal peptide and a propeptide that are thought to be cleaved during synthesis (Fig. 1A) . In this study, amino acids were numbered beginning with the first residue of the putative mature protein. Alignment of the mature N-terminal sequences of human and murine PSGL-1 revealed similarities but also important differences (Fig. 1B) . Each protein has tyrosine residues within a region rich in acidic amino acids that favors tyrosine sulfation. Human PSGL-1 has three tyrosines at residues 5, 7, and 10, all of which are sulfated and contribute to binding to Pselectin 17, 20 . A 5-residue segment containing a proline separates the tyrosines from a threonine at residue 16; the latter residue is modified with a core-2 O-glycan capped with sLe x that is also required for binding to P-selectin 17, 19 . By contrast, murine PSGL-1 has only two tyrosines at residues 13 and 15. These are very close to threonines 14 and 17, the only residues in the N-terminal region that might be O-glycosylated.
To determine whether the tyrosine and threonine residues contributed to binding of murine PSGL-1 to P-selectin, we made a series of constructs in which we altered these residues either individually or in combination (Fig. 1C) . We also prepared a construct with mutations in the third residue of each sequon for the two potential N-glycosylation sites at residues 25 and 209. The cDNA encoding each construct was transfected into CHO cells that were previously transfected with expression vectors encoding
Core2GlcNAcT-I and FTVII. Fluorescence activated cell sorting was used to isolate clones that expressed matched levels of wild-type murine PSGL-1 or each mutant PSGL-1 construct (Fig. 2) . Each clone expressed similar levels of Core2GlcNAcT-I and FTVII, as measured by binding of mAbs to the T antigen and to sLe x , respectively (Table 1) . 3A ). P-selectin-IgM bound equivalently to wild-type PSGL-1 and to the Y15F and T14A
constructs, demonstrating that neither Tyr-15 nor Thr-14 is required for binding to Pselectin in this assay (Fig. 3B) . P-selectin-IgM also bound normally to the T27/S211A
construct, indicating that the N-glycosylation sites are not required for binding. However, P-selectin-IgM binding to the Y13F and T17A constructs was substantially decreased.
The residual binding was specific, because it was blocked by EDTA or by mAb 4RA10
(data not shown). Mutation of both tyrosines (Y13/15F) or both threonines (T14/17A) did not further reduce binding, whereas mutation of all four residues eliminated binding (Fig.   3B ). Eight-fold higher concentrations of P-selectin-IgM did not detectably increase binding to cells expressing either wild-type or mutant PSGL-1 (data not shown). These results demonstrate that Tyr-13 and Thr-17 make major contributions to binding, whereas the adjacent Tyr-15 and Thr-14 do not.
As an independent assay for interactions of murine PSGL-1 with P-selectin, we measured tethering and rolling of transfected CHO cells on immobilized P-selectin under flow. Equivalent numbers of CHO cells expressing wild-type PSGL-1 or the Y15F or T14A constructs rolled on P-selectin-IgM at all wall shear stresses examined (Fig. 4A ).
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Frame-by -frame analysis revealed that the cells expressing these constructs rolled with similar mean velocities and variances of velocity (data not shown) and resisted detachment similarly in response to increasing wall shear stress (Fig. 4B) . Furthermore, flowing cells tethered to P-selectin at similar rates (Fig. 4C) . Thus, neither Tyr-15 nor Thr-14 is required for cells to interact with P-selectin under the flow conditions examined. In contrast, substantially fewer cells expressing Y13F, T17A, or the doubletyrosine or double-threonine mutations rolled on P-selectin, and this rolling was observed only at low wall shear stresses (Fig. 4A) . The residual rolling was specific, because mAb 4RA10 eliminated rolling (data not shown). However, the residual cells rolled irregularly and detached much more readily in response to increasing wall shear stress (Fig. 4B) .
Furthermore, fewer flowing cells expressing Y13F, T17A, or the double-tyrosine or double-threonine mutations tethered to P-selectin (Fig. 4C) . Cells expressing the construct in which all tyrosines and threonines were mutated exhibited no PSGL-1-dependent tethering to or rolling on P-selectin (Fig. 4, A and C) . Similar results were observed when tethering and rolling of cells on immobilized human P-selectin was measured (data not shown). These results demonstrate that Tyr-13 and Thr-17 make major contributions to tethering and rolling of cells expressing murine PSGL-1 on Pselectin under flow, whereas Tyr-15 and Thr-14 do not.
Inhibition of sulfation markedly reduces binding of murine PSGL-1 to P-selectin-
-Human PSGL-1 requires sulfation of each of its three N-terminal tyrosines to interact optimally with P-selectin 20 . To determine whether sulfation of murine PSGL-1 enhances binding to P-selectin, we cultured CHO cells expressing wild-type or Y13/15F murine PSGL-1 in the presence or absence of the sulfation inhibitor chlorate for three days to allow turnover of previously sulfated molecules. Chlorate is a selective inhibitor of ATP For personal use only. on September 14, 2017. by guest www.bloodjournal.org From 13 sulfurylase (ATP sulfate adenylyltransferase), which is required for formation of phosphoadenosine phosphosulfate (PAPS), the donor for sulfation reactions. Chloratetreated cells expressing wild-type PSGL-1 bound much less P-selectin-IgM, to a level similar to that observed for untreated cells expressing Y13/15F PSGL-1 (Fig. 5A ).
Chlorate treatment of cells expressing Y13/15F did not further reduce binding of Pselectin-IgM. Chlorate treatment also substantially decreased rolling of cells expressing wild-type PSGL-1 on immobilized P-selectin under flow (Fig. 5B) . Chlorate treatment did not further reduce rolling of CHO cells expressing Y13/15F PSGL-1 on P-selectin (data not shown). These results demonstrate that sulfation of murine PSGL-1 contributes significantly to binding to P-selectin, and further suggest that sulfation of tyrosine is required for optimal binding.
Cells expressing murine PSGL-1 must co-express Core2GlcNAcT-I and FTVII to
interact with P-selectin--Human PSGL-1 must express a core-2 O-glycan capped with sLe x at Thr-16 to bind detectably to P-selectin [15] [16] [17] 19 , and very few leukocytes from mice lacking Core2GlcNAcT-I or FTVII roll on P-selectin 30,31 . To confirm that these glycosyltransferases must modify murine PSGL-1 expressed in CHO cells to confer binding to P-selectin, we expressed wild-type murine PSGL -1 or the Y13/15F or T14/17A constructs in parental CHO cells or in transfected CHO cells co-expressing FTVII but not Core2GlcNAcT-I. CHO cell clones were selected that expressed matched levels of PSGL-1 (Fig. 6 ) or FTVII (Table 1) . Virtually no parental cells or cells expressing FTVII rolled on P-selectin, regardless of whether PSGL-1 was expressed (data not shown). As a more sensitive assay, we looked for transient tethers of flowing cells to P-selectin. A very small number of cells expressing FTVII tethered transiently to Pselectin at a very low wall shear stress, but none of these tethers converted to even brief (Fig. 7) . These transient tethers required expression of FTVII, because they were not observed in parental CHO cells. They did not require PSGL-1, because the number of tethers was not increased in cells expressing wild-type or mutant PSGL-1.
Significantly more cells expressing wild-type or mutant PSGL-1 tethered to P-selectin when they co-expressed both Core2GlcNAcT-I and FTVII. These tethers required PSGL-1, because anti-PSGL-1 mAb 4RA10 eliminated them (data not shown), and cells expressing both glycosyltransferases in the absence of PSGL-1 formed only a few transient tethers like those seen in cells expressing only FTVII. These data confirm that murine PSGL-1 expressed in CHO cells must be modified with both Core2GlcNAcT-I and FTVII to bind P-selectin. It is noteworthy that cells expressing the T14/17A construct tethered to and rolled on P-selectin much more readily when they co-expressed both Core2GlcNAcT-I and FTVII. This suggests that murine PSGL-1 may utilize a core-2 Oglycan(s) on a residue other than Thr-17 to also contribute to optimal binding to Pselectin. Alternatively, CHO cells may express one or more core-2 O-glycans on proteins other than PSGL-1 that facilitate binding. The putative O-glycan(s) is likely to cooperate with Tyr-13 or perhaps Tyr-15, because simultaneous mutation of Tyr-13, Tyr-15, Thr-14, and Thr-17 eliminated tethering to P-selectin even when the cells expressed both glycosyltransferases (Fig. 4C) . However, our data imply that murine PSGL-1 differs significantly from human PSGL-1 in the relative contributions of tyrosine sulfate, peptide components, and glycosylation that it uses to bind to P-selectin.
The N-terminal region of murine PSGL-1 has two tyrosines, Tyr-13 and Tyr-15, which could be sulfated, and two threonines, Thr-14 and Thr-17, which could be Oglycosylated. Assays of mutated forms of murine PSGL-1 strongly suggest that only Tyr-13 and Thr-17 contribute to binding to murine P-selectin. Mutation of either Tyr-13 or Thr-17 markedly decreased interactions with P-selectin. In contrast, mutation of either Tyr-15 or Thr-14 did not detectably affect binding, and mutation of both tyrosines or both
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Validation of this interpretation will require direct studies with semi-synthetic glycosulfopeptides, where sulfation and glycosylation can be modified without mutation of amino acids 19, 20 . Inhibition of sulfation with chlorate markedly diminished binding of murine PSGL-1 to P-selectin, providing independent evidence for the importance of sulfation in binding. The failure of chlorate to diminish the residual binding of Y13/15
PSGL-1 to P-selectin suggests that optimal binding requires sulfation of tyrosine.
Algorithms for consensus sequences suggest that O-glycosylation is more likely to occur on Thr-17 than on Thr-14 44 . Tyrosine sulfation occurs primarily in the trans-Golgi network, and is therefore likely to occur after the initial steps of O-glycosylation 45 . Oglycosylation of Thr-17 might sterically inhibit sulfation of Tyr-15 but not of the potentially more distant Tyr-13.
Our data suggest that murine PSGL-1 requires only one tyrosine, which may be sulfated, plus a core-2 O-glycan to bind to P-selectin. This differs significantly from human PSGL-1, where each of three tyrosine sulfates contributes to the affinity of binding to P-selectin. Indeed, crystallographic studies reveal that at least two of the three tyrosine sulfates of human PSGL-1 bind directly to amino acids in the lectin domain of human P-selectin 21 . The relative affinities of murine and human PSGL-1 for P-selectin are not known. Perhaps the decrease in sulfation of murine PSGL-1 lowers its affinity for murine (or human) P-selectin. Alternatively, N-terminal peptide components unique to murine PSGL-1 may provide compensatory binding sites for P-selectin so there is no net loss of binding affinity. Both biochemical and structural evidence indicates that peptide
For personal use only. on September 14, 2017. by guest www.bloodjournal.org From components other than tyrosine sulfate enhance binding of human PSGL-1 to P-selectin 20, 21 . These components could be even more important in murine PSGL-1. This might explain why mutation of the tyrosines or prevention of sulfation of murine PSGL-1 reduces, but does not eliminate, binding to P-selectin, whereas mutation of tyrosines or removal of sulfate on human PSGL-1 more profoundly inhibits binding. Thus, peptide and tyrosine sulfate components in the N-terminal region of murine PSGL-1 might be sufficient to mediate the residual binding to P-selectin observed after mutation of both Thr-14 and Thr-17. Loss of O-glycosylation might even permit sulfation of Tyr-15, which normally may not be modified. However, the T14/17A PSGL-1 construct bound to P-selectin only when it was co-expressed with both Core2GlcNAcT-I and FTVII. This suggests that a core-2 O-glycan capped with sLe Direct binding studies with purified murine PSGL-1 constructs will be required to distinguish these possibilities. Whatever the mechanism, weak binding to P-selectin persists after mutation of Thr-14 and Thr-17 in murine PSGL-1, whereas binding to Pselectin is virtually eliminated after mutation of Thr-16 in human PSGL-1 15, 17 . Taken together, these data argue for important differences in the relative contributions of tyrosine sulfate, peptide components, and O-glycosylation to binding of murine and human PSGL-1 to P-selectin.
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The site-directed mutagenesis results presented here should be interpreted cautiously, since mutations may impair function by indirect structural alterations.
Furthermore, we co-expressed murine PSGL-1 with specific glycosyltransferases in transfected CHO cells, which may modify PSGL-1 differently than do murine leukocytes.
Nevertheless our results suggest both similarities and interesting differences in how murine and human PSGL-1 bind to P-selectin. Direct comparisons of binding affinities of murine and human PSGL-1 with murine and human P-selectin will provide additional insights. Complementary information will be obtained from studies with glycosulfopeptides modeled after PSGL-1, where precise changes in peptide sequence, sulfation, and glycosylation can be made. Finally, it will be important to determine the structures of oligosaccharides on murine leukocytes, particularly those on PSGL-1. Such information may be useful for interpreting the degree to which in vivo studies of selectin-PSGL-1 interactions in mice can be extended to human physiology. For some points, the error bars are smaller than the data symbols.
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